For more than 15 years, our team has been working on the pathophysiology of dyslipidemia in humans, mostly dyslipidemia associated with diabetes and insulin-resistance. Patients with diabetes and individuals with insulin-resistance (Metabolic Syndrome) show a very high cardiovascular risk that is largely promoted by the atherogenic dyslipidemia associated with diabetes and insulin resistance.